IQVIA因利息支出高企，预测年度利润疲软

Core Viewpoint - IQVIA Holdings has released its 2026 earnings forecast, which is below Wall Street expectations due to rising interest expenses, despite strong fourth-quarter performance indicating improved demand from pharmaceutical clients [1][2] Group 1: Earnings Forecast and Financial Performance - For 2026, IQVIA expects adjusted earnings per share to be in the range of $12.55 to $12.85, lower than the analyst average estimate of $12.95 [1] - The forecast reflects increased interest expenses from financing activities completed in 2025 and an anticipated refinancing cost of nearly $8 million in 2026 [1] - In the fourth quarter, IQVIA reported adjusted earnings per share of $3.42 and revenue of $4.36 billion, exceeding analyst expectations of $3.40 and $4.24 billion, respectively [2] - The research solutions segment, which provides clinical trial services, generated fourth-quarter revenue of $2.33 billion, surpassing the expected $2.29 billion [2] Group 2: Market Conditions and Industry Trends - The contract research and data analytics sector is facing ongoing challenges, with cautious financing in the biotechnology sector and extended decision-making cycles [1] - Evercore ISI analyst Elizabeth Anderson highlighted investor focus on the potential impact of artificial intelligence on drug development and professional services, as well as how IQVIA can leverage these tools to capture market share and create value for clients [2] Group 3: Business Restructuring - IQVIA announced a business segment reorganization effective January 1, 2026, merging its contract sales business with the technology and data analytics department to form a new "Commercial Solutions" segment, while transferring part of its real-world research business to the research segment [2]